ARTICLE | Clinical News
Genmab Humax-CD4 Phase II psoriasis data
November 12, 2001 8:00 AM UTC
Genmab (CSE:GEN, NMarkt:GE9D) said that initial data from 79 of 85 psoriasis patients in a Phase II study of its Humax-CD4 antibody showed a significant dose response in doses up to 160 mg. In the 160...